Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature
Open Access
- 1 May 2018
- journal article
- research article
- Published by Bioscientifica in Endocrine Connections
- Vol. 7 (5) , 708-718
Abstract
Objective: There is a scarcity of data from randomised controlled trials on the association of growth hormone (GH) with gonadotrophin-releasing hormone agonists in idiopathic short stature (ISS), although this off-label use is common. We aimed to test whether delaying pubertal progression could increase near-adult height (NAH) in GH-treated patients with ISS. Methods: Patients with ISS at puberty onset were randomised to GH with leuprorelin (combination, n = 46) or GH alone ( n = 45). NAH standard deviation score (SDS) was the primary outcome measure. The French regulatory authority requested premature discontinuation of study treatments after approximately 2.4 years; patients from France were followed for safety. Results: Mean ( s.d. ) baseline height SDS was −2.5 (0.5) in both groups, increasing at 2 years to −2.3 (0.6) with combination and −1.8 (0.7) with GH alone. NAH SDS was −1.8 (0.5) with combination ( n = 19) and −1.9 (0.8) with GH alone ( n = 16). Treatment-emergent adverse events and bone fractures occurred more frequently with combination than GH alone. Conclusion: Due to premature discontinuation of treatments, statistical comparison of NAH SDS between the two cohorts was not possible. During the first 2–3 years of treatment, patients treated with the combination grew more slowly than those receiving GH alone. However, mean NAH SDS was similar in the two groups. No new GH-related safety concerns were revealed. A potentially deleterious effect of combined treatment on bone fracture incidence was identified.Keywords
This publication has 32 references indexed in Scilit:
- Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious PubertyInternational Journal of Endocrinology, 2015
- Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?Journal of Pediatric Endocrinology and Metabolism, 2012
- Safety of Growth Hormone Treatment of Children with Idiopathic Short Stature: The US ExperienceHormone Research in Paediatrics, 2011
- Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic reviewBMJ, 2011
- Use of GnRH agonists in GH-deficient patients: arguments for and against. The case for GnRH agonists in GH-deficient patients.2008
- Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive FunctionThe Journal of Clinical Endocrinology & Metabolism, 2008
- Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short StatureHormone Research in Paediatrics, 2007
- Can we increase adolescent growth?European Journal of Endocrinology, 2004
- The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and AdolescentsPediatrics, 2004
- Tables for predicting adult height from skeletal age: Revised for use with the greulich-pyle hand standardsThe Journal of Pediatrics, 1952